Kindred Biosciences (KIN) Tops Q4 EPS by 1c

Kindred Biosciences (NASDAQ: KIN) reported Q4 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $951 thousand versus the consensus estimate of $1 million.

For earnings history and earnings-related data on Kindred Biosciences (KIN) click here.

You May Also Be Interested In

• Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
• First Industrial Realty (FR) Tops Q1 EPS by 21c
• CSX reiterates FY outlook as Q1 results top estimates